Miller

Home

News
2017-08-10:

CSB has been named as one of the NCI Innovative Research in Cancer Nanotechnology (IRCNs). The IRCNs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.

2017-02-09:

Miles Miller, PhD and Kevin King, MD, PhD have been selected to serve as Associate Scientific Advisors (ASAs) for Science's sister journal, Science Translational Medicine, for 2017-2018.